Skip to main content
Scientist at the lab)


Driven by Our Patients

Immunology Congress Materials

Congress Materials


Meet Us at an Event

AAAAI 2023 24–27 Feb 2023 San Antonio, Texas USA Details
EAACI 2023 9–11 Jun 2023 Hamburg, Germany Details
PNS 2023 17–20 June 2023 Copenhagen, Denmark Details

Immunology Resources

Person at a laptop

HAE Interactive Patient Case Study Tool: Test your knowledge and understanding of managing patients with HAE

Person reading tablet

Patient Case Study Infographics: Learn more about real- world experience of subcutaneous Berinert® 2000/3000 (C1-INH)

Prescribing information for HAEGARDA® and Berinert® may vary depending on local approval in each country. Therefore, before prescribing HAEGARDA® or Berinert®, always refer to local materials such as the prescribing information and/or the Summary of Product Characteristics (SmPC) in your country.

HAEGARDA® and Berinert® are not available in all countries. Consult the CSL Behring Global Products List to see if HAEGARDA® and Berinert® are available in your country.


  1. CSL Ltd Annual Report 2022. CSL Ltd. Published 2022. Accessed September 6, 2022.

August 2021